Aspira Women’s Health (NASDAQ:AWH) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Aspira Women’s Health (NASDAQ:AWH) announced its quarterly earnings data on Tuesday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03), Zacks reports. Aspira Women’s Health had a negative net margin of 163.95% and a negative return on equity of 1,099.32%. The firm had revenue of $2.15 million for the quarter, compared to analyst estimates of $2.10 million. During the same quarter in the previous year, the company earned ($10.94) EPS.

Aspira Women’s Health Price Performance

Shares of AWH stock opened at $2.58 on Thursday. Aspira Women’s Health has a 12-month low of $2.17 and a 12-month high of $6.75. The business has a 50 day simple moving average of $3.18 and a 200 day simple moving average of $3.72.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on AWH. StockNews.com initiated coverage on Aspira Women’s Health in a research note on Tuesday. They set a “hold” rating on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $3.30 target price on shares of Aspira Women’s Health in a report on Wednesday, April 10th.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.